Supplement Article
www.jaids.com J Acquir Immune Defic Syndr Volume 78, Supplement 1, August 15, 2018
Le gouvernement du Sénégal a mis à jour son engagement au Sommet sur la planification familiale à Londres, RoyaumeUni, le 11 juillet 2017.
Le texte qui suit résume l’engagement pris par le Dr Awa Marie Coll-Seck au nom du gouvernement du Sénégal le 11 juillet 2012, lors du Sommet de Londre...s sur la planification familiale.
more
2020 is a critical year for our Joint Programme as we collectively define the path to getting back on track to ending the AIDS epidemic by 2030. Our revised timelines for adoption of the next strategy are highly ambitious. We need the full support of all the tremendously dedicated people in UNAIDS-w...ithin our staff, our board and all our stakeholders to make this happen.
more
Practices, challenges and the future implications for all stakeholders
United Nations Office of the Resident Coordinator | http://www.unlesotho.org/
Neurology, Published online before print 15 Jul 2016. Open Access
The 2019 edition treating data for 2018 marks sustained international efforts dedicated to reporting on, analysing and understanding the year-to-year variations and long-term trends of a changing climate.
June 2020In die Skriflig/In Luce Verbi 54(1)
DOI: 10.4102/ids.v54i1.2562
Operation update 01/04/2022
Clinical Medicine
JCI Insight. 2017;2(7):e91963.
IAEA Safety Standards for protecting people and the environment
sthma prevalence is increasing worldwide, and surveys indicate that most patients in developed and developing countries, including South Africa, do not receive optimal care and are therefore not well controlled. Standard management guidelines adapted to in-country realities are important to support ...optimal care. The South African Thoracic Society (SATS) first published a guideline for the management of chronic persistent asthma in 1992, which has subsequently been revised several times.
The main aim of the present document was to revise and update SATS’ statement on the suggested management of chronic asthma, based on the need to promote optimal care and control of asthma, together with the incorporation of new concepts and drug developments. This revised document reinforces optimal care and incorporates the following primary objectives to achieve the recent advances in asthma care:
• continued emphasis on the use of inhaled corticosteroids (ICS) as the foundation of asthma treatment
• to reduce the reliance on short-acting beta-2 agonist (SABA) monotherapy for asthma symptoms
• to incorporate the evidence and strategy for the use of the combination of an ICS and formoterol for acute symptom relief (instead of a SABA)
• to incorporate the evidence and strategy for the use of as-needed ICS-long-acting beta agonists (LABA) for patients with infrequent symptoms or ‘mild’ asthma
• to incorporate the evidence and strategy for the use of a long-acting muscarinic antagonist (LAMA) in combination with ICS-LABA; and
• to incorporate the evidence and strategy for the use of and management with a biologic therapy in severe asthma.
more